<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346200</url>
  </required_header>
  <id_info>
    <org_study_id>2016-000882-22</org_study_id>
    <nct_id>NCT03346200</nct_id>
  </id_info>
  <brief_title>Karma Intervention Study</brief_title>
  <acronym>Karisma 2</acronym>
  <official_title>A Randomised, Double Blinded, Six-armed Placebo Controlled Study to Investigate Optimal Dose of Tamoxifen With the Most Favourable Side Effect Spectre and With Mammography Density Reduction Non-inferior to That of 20 mg Tamoxifen (Karisma 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Hall</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose determination study aiming to identify the optimal tamoxifen dose for reducing&#xD;
      the risk of breast cancer. Instead of following a very large number of women, for many years,&#xD;
      treated with different doses of tamoxifen and see if they develop breast cancer, the&#xD;
      investigators will include 1,440 healthy women participating in the mammographic screening&#xD;
      program at two Mammography units (Unilabs mammography, Lund and Södersjukhuset Breast Centre,&#xD;
      Stockholm) and measure their change in mammographic density. The change in mammographic&#xD;
      density is a very good marker of therapy response. Investigators will test if 1 mg, 2.5 mg, 5&#xD;
      mg and 10 mg reduce the mammographic density to the same extent as 20 mg. In summary Karisma&#xD;
      2 will be a randomized, double-blinded, six-armed placebo controlled study to identify the&#xD;
      dose of tamoxifen with the most favourable side effect spectra and with a density reduction&#xD;
      non-inferior to 20 mg tamoxifen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mammograpic density change</measure>
    <time_frame>6 months treatment</time_frame>
    <description>Change in mammography density. In particular, we will test for noninferiority in the proportion of women in the intervention arms (placebo, 1 mg, 2.5 mg, 5 mg, 10 mg) who have a density reduction as great as or greater (after 6 months) than the median density reduction in the 20 mg arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of side effects</measure>
    <time_frame>During time of treatment (6 months)</time_frame>
    <description>Assess the level of side effects in the intervention arms compared to the 20 mg arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop out level</measure>
    <time_frame>During time of treatment (6 months)</time_frame>
    <description>Assess the level of drop out in the intervention arms compared to the 20 mg arm</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1440</enrollment>
  <condition>Risk Reduction</condition>
  <condition>Mammographic Density Reduction</condition>
  <arm_group>
    <arm_group_label>20 mg tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5 mg tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0 mg tamoxifen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen Oral Tablet</intervention_name>
    <description>Randomised dose of tamoxifen 1 pill/day for 180 days</description>
    <arm_group_label>1 mg tamoxifen</arm_group_label>
    <arm_group_label>10 mg tamoxifen</arm_group_label>
    <arm_group_label>2.5 mg tamoxifen</arm_group_label>
    <arm_group_label>20 mg tamoxifen</arm_group_label>
    <arm_group_label>5 mg tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Randomised dose of tamoxifen 1 pill/day for 180 days</description>
    <arm_group_label>0 mg tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Attending the national mammography screening program, i.e. aged 40-74 and has&#xD;
             performed a screening mammogram maximum 3 months prior to study inclusion&#xD;
&#xD;
          -  Having a measurable mammographic density, i.e. ≥4.5 % density (volumetric) measured by&#xD;
             Volpara&#xD;
&#xD;
          -  Informed consent must be signed before any study specific assessments have been&#xD;
             performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy at start, during time of study medication and up to 3 months after quitting&#xD;
             study medication&#xD;
&#xD;
          -  Any previous or current diagnosis of breast cancer (including carcinoma in situ)&#xD;
&#xD;
          -  Mammographic BI-RADS code 3 or above at baseline mammography, or at a diagnostic&#xD;
             mammography during time of treatment (the first 6 months of the study)&#xD;
&#xD;
          -  Any previous diagnosis of cancer with the exception of non-melanoma skin cancer and in&#xD;
             situ cancer of the cervix&#xD;
&#xD;
          -  Currently using oral oestrogen and progesterone based hormone replacement therapy&#xD;
&#xD;
          -  Current use of hormone contraceptive with hormones, e.g. hormonal contraceptive pills,&#xD;
             or progesterone implants. Hormonal intrauterine devices are accepted.&#xD;
&#xD;
          -  A history of thrombo-embolic disease such as embolies, deep vein thrombosis, stroke,&#xD;
             TIA or cardiac arrest.&#xD;
&#xD;
          -  Known APC (Activated protein C )- resistance, an inherited hemostatic disorder&#xD;
&#xD;
          -  A history of major surgery of the breast, e.g. reduction or enlargement, which might&#xD;
             affect density measurements&#xD;
&#xD;
          -  Women who have an increased risk of venous thrombosis due to immobilization, e.g.&#xD;
             using wheelchair&#xD;
&#xD;
          -  Known uncontrolled diabetes&#xD;
&#xD;
          -  Hypertension at baseline, defined as systolic pressure higher than 140 mm Hg and&#xD;
             diastolic higher than 90 mm Hg&#xD;
&#xD;
          -  Use of drugs that interfere with CYP2D6 expression such as Seroxat (paroxetine),&#xD;
             Fontex (fluoxetin) and Zyban / Voxra (bupropion)&#xD;
&#xD;
          -  Use of Waran (warfarin)&#xD;
&#xD;
          -  Non-medical approved drugs against hot-flashes including phytooestrogen&#xD;
&#xD;
          -  Not able to understand study information and/or informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female mammography screening population in Sweden age 40-74</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Per Hall</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

